Fig. 3 | Scientific Reports

Fig. 3

From: Longitudinal analysis of neutralizing antibodies against SARS-CoV-1 and different SARS-CoV-2 strains in breakthrough and unvaccinated COVID-19 patients in Thailand (2021-2022)

Fig. 3

Neutralizing antibodies against the SARS-CoV-2 ancestral strain and variants on day 0 in 111 COVID-19 patients. The nAbs were determined using the multiplex surrogate virus neutralization test (sVNT) assay on plasma samples from patients who were unvaccinated (N = 17) and those who received a homologous inactivated virus vaccine (CoronaVac or BBIBP-CorV) (N = 10), homologous viral vector vaccine (ChAdOx1-S) (N = 31), homologous mRNA vaccine (BNT162b2 or mRNA-1273) (N = 4), and heterologous vaccine (all vaccine combinations) (N = 49). The Mann–Whitney U test was used to compare the median differences between groups. Numbers on the graph represent the median percent inhibition of nAbs. A percentage of inhibition value of less than 30% was considered a negative result (indicated by the dotted red line). ***, p < 0.001; **, p < 0.010, and *, p < 0.050. The bars in the graphs represent the interquartile range (IQR). Neutralizing antibody data for 111 COVID-19 patients were partially obtained from a previously published dataset33.

Back to article page